Back to News & Events

Roche Oncology: Strategic Interests Presentation

Join the Center for Biotechnology for Roche Oncology Strategic Interests Presentation on Monday April 15, 2019.

Fiona Mack, PhD, Director External Innovation, Pharmaceutical Research and Early Development for the Roche Innovation Center New York will be at Stony Brook University Medical Center to present Roche’s strategic interests in Oncology, the process for asset evaluation and the various partnership models available to support discovery and early development programs. Fiona will also discuss Roche’s approach to investing in emerging novel therapeutics utilizing case studies as examples.

April 15, 2019
10am-11am
Radiation Oncology Conference Room (HOS L2-664)
Stony Brook University Medical Center Level 2

Seating is limited. If you are interested in attending please contact Emily Kao at emily.kao@stonybrook.edu

How to get to Stony Brook University Hospital Radiation Oncology Conference Room
To access the Radiation Oncology Conference Room, please utilize the hospital main elevators and take down to Level 2. When you arrive on Level two proceed forward, following the signs to the “green elevators”. You will find the Radiation Oncology conference room on your right hand side, room HOS L2-664

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:50:15 [post_modified_gmt] => 2024-11-19 15:50:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 2350 [post_author] => 3 [post_date] => 2016-07-19 19:15:50 [post_date_gmt] => 2016-07-19 19:15:50 [post_content] => Rosyln Heights, NY-based Ortek Therapeutics announced that the U.S. Patent and Trademark Office has awarded a patent for new methods to use new compositions to prevent or treat drug-resistant bacteria and suppress body odor. U.S. Patent 9,370,476, was issued to The Research Foundation of State University of New York, an Ortek licensing partner, and is directed to topical application of a zinc and arginine-based composition. Ortek holds exclusive international licensing rights to this patent, which was developed at Stony Brook University. Ortek has a long-standing relationship with Israel Kleinberg DDS, PhD, DSc, who led the development of this new technology and is the Director of the Division of Translational Oral Biology at Stony Brook University. [post_title] => Ortek Therapeutics Announces New Patent for Microbiome Technology [post_excerpt] => Ortek Therapeutics announced that the U.S. Patent and Trademark Office has awarded a patent for new methods to use new compositions to prevent or treat drug-resistant bacteria and suppress body odor. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => ortek-therapeutics-announces-new-patent-for-microbiome-technology [to_ping] => [pinged] => [post_modified] => 2016-08-04 17:24:47 [post_modified_gmt] => 2016-08-04 17:24:47 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2350 [menu_order] => 170 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3856 [post_author] => 3 [post_date] => 2021-12-06 15:25:03 [post_date_gmt] => 2021-12-06 15:25:03 [post_content] =>

NYSTAR reviews and coordinates requests for New York State matching grants and support letters to strengthen applicants' proposals to federal agencies, foundations, and other grant-making organizations. The purpose of this program is to attract more federal R&D funding to support technology development and commercialization efforts in New York State.

While funding is available, NYSTAR will accept applications monthly with a submission deadline of the 20th. The first Round will have a deadline for application submission of January 20, 2022.

Learn more and apply here: https://esd.ny.gov/matching-grants-leverage-program

[post_title] => NYS Matching Grants Leverage Program [post_excerpt] => NYSTAR reviews and coordinates requests for New York State matching grants and support letters to strengthen applicants' proposals to federal agencies, foundations, and other grant-making organizations. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => nys-matching-grants-leverage-program [to_ping] => [pinged] => [post_modified] => 2021-12-06 15:25:05 [post_modified_gmt] => 2021-12-06 15:25:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3856 [menu_order] => 30 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 4470 [post_author] => 4 [post_date] => 2024-08-28 10:13:57 [post_date_gmt] => 2024-08-28 14:13:57 [post_content] =>

The Long Island High Technology Incubator (LIHTI) is inviting innovative and entrepreneurial individuals, with advanced training in STEMM disciplines, to join our team to support our Venture Champions Initiative. The VC Fellowship is powered by the LIHTI team, working collaboratively with a wide network of mentors and industry partners. In the long term, this fellowship aims to generate a pipeline of trained, entrepreneurially-minded fellows as well as a pool of commercially viable technologies for the Long Island Innovation ecosystem. Apply here to chart your commercialization career in hard tech.

[post_title] => LIHTI Venture Champion Fellowship [post_excerpt] => The Long Island High Technology Incubator is recruiting candidates for its Venture Champions Fellowship. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => lihti-fellowship24 [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:46:47 [post_modified_gmt] => 2024-11-19 15:46:47 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4470 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4439 [post_author] => 3 [post_date] => 2024-07-30 15:29:07 [post_date_gmt] => 2024-07-30 19:29:07 [post_content] =>

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:50:15 [post_modified_gmt] => 2024-11-19 15:50:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 261 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant

More Information

Ortek Therapeutics Announces New Patent for Microbiome Technology

More Information

NYS Matching Grants Leverage Program

More Information

LIHTI Venture Champion Fellowship

More Information